文献速递外周动脉疾病

膝下假体旁路术后DOAC与无截肢生存改善相关

Postoperative Direct Oral Anticoagulants are Associated with Improved Amputation-Free Survival in Infrageniculate Bypasses Performed by Prosthetic Grafts in Patients with Chronic Limb-Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2025-05-29

调整混杂后,华法林和DOAC均与1年及3年死亡风险降低相关;华法林与3年大截肢风险升高相关,DOAC无此风险;3年时DOAC的无截肢生存优于华法林。作者认为该研究支持在假体移植物IGB中使用抗凝药、优先DOAC,但需前瞻性研究证实。

要点

  • 出院华法林与DOAC均与1年及3年死亡风险降低相关,DOAC与3年大截肢风险升高无关。
  • 3年时DOAC组无截肢生存优于华法林组(aHR 0.76,95%CI 0.58-0.99,P=0.045)。
  • 华法林组3年大截肢风险高于未抗凝组(aHR 1.33,95%CI 1.03-1.72,P=0.029)。

核心结论

  • IGB使用PTFE移植物患者术后抗凝与生存改善相关,DOAC组3年无截肢生存优于华法林组;作者认为支持使用抗凝药、优先DOAC,但需前瞻性研究证实。

研究设计与样本

  • 按出院抗凝状态分为未抗凝组(N=1,170,63.5%)、华法林组(N=482,26.2%)和DOAC组(N=189,10.3%);DOAC包括利伐沙班或达比加群。
  • 采用Kaplan-Meier生存估计和Cox回归分析;主要结局为无截肢生存(AFS)。

主要发现

  • 与未抗凝相比,出院华法林与1年死亡风险降低相关(aHR 0.60,95%CI 0.46-0.78,P<0.001),DOAC与1年死亡风险降低相关(aHR 0.63,95%CI 0.43-0.93,P=0.021)。
  • 与未抗凝相比,华法林与3年死亡风险降低相关(aHR 0.72,95%CI 0.59-0.89,P=0.002),DOAC与3年死亡风险降低相关(aHR 0.64,95%CI 0.45-0.90,P=0.011)。
  • 华法林组3年大截肢风险高于未抗凝组(aHR 1.33,95%CI 1.03-1.72,P=0.029);DOAC组未见大截肢风险升高。
  • 3年时DOAC组AFS优于华法林组(aHR 0.76,95%CI 0.58-0.99,P=0.045)。
  • 与未抗凝相比,华法林和DOAC在3年随访中均与再干预无关。

临床怎么用

  • 对使用PTFE移植物行膝下旁路的CLTI患者,术后可考虑抗凝,DOAC或优先于华法林以改善结局(原文结论性表述)。
  • 华法林组3年大截肢风险高于未抗凝组,DOAC组未见该风险升高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autogenous single-segment great saphenous vein graft is the conduit of choice in infrainguinal bypasses particularly when the distal target of bypass is infra-geniculate. However, use of prosthetic grafts for infrageniculate bypass (IGB) is required in certain patients. Different measures have been used to increase the durability of prosthetic grafts in IGB. We aimed to investigate the effect of postoperative anticoagulation on outcomes of IGBs performed by prosthetic conduits in patients with chronic limb-threatening ischemia (CLTI). METHODS: The Vascular Quality Initiative-Medicare-linked database was queried for IGBs performed for CLTI (rest pain or tissue loss) between May 2014 and December 2019. All included patients underwent IGB by polytetrafluoroethylene (PTFE) grafts. The patients were stratified based on postoperative anticoagulation status: no discharge anticoagulation, warfarin, and direct oral anticoagulants (DOACs). DOACs included rivaroxaban or dabigatran. The primary outcome was amputation-free survival (AFS). Secondary outcomes were overall survival, limb salvage, and freedom from reintervention. Kaplan-Meier survival estimates and Cox regression were used for statistical analysis. RESULTS: The study included 3 cohorts: No discharge anticoagulation (N = 1,170, 63.5%), warfarin (N = 482, 26.2%), and DOAC (N = 189, 10.3%). After adjusting for potential confounders, discharge warfarin and DOAC were associated with lower risk of death in 1 year (adjusted hazard ratio [aHR], 0.60 [95% confidence interval {CI}: 0.46-0.78], P < 0.001 and aHR, 0.63 [95% CI: 0.43-0.93], P = 0.021, respectively) and 3 years (aHR, 0.72 [95% CI: 0.59-0.89], P = 0.002 and aHR, 0.64 [95% CI: 0.45-0.90], P = 0.011, respectively) compared to no anticoagulation. Patients receiving warfarin were at greater risk of major amputation at 3 years postoperatively (aHR, 1.33 [95% CI: 1.03-1.72], P = 0.029) than the nonanticoagulated patients, while patients receiving DOACs did not have a greater risk of major amputation. At 3 years, DOAC was associated with improved AFS compared to warfarin (aHR, 0.76 [95% CI: 0.58-0.99], P = 0.045). Neither warfarin nor DOAC was associated with reintervention at 3-year follow-up compared to no anticoagulation. CONCLUSION: We found that postoperative anticoagulation use was associated with improved survival in patients undergoing IGB with PTFE graft for CLTI. Moreover, patients receiving DOACs were associated with greater AFS at 3 years postoperatively than warfarin. This study supports the use of anticoagulants, DOAC preferably to achieve favorable outcomes in IGBs when a prosthetic graft is being used. However, further prospective studies are necessary to confirm our findings.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zarrintan S, Abdelkarim A, Powell JJ, et al. Postoperative Direct Oral Anticoagulants are Associated with Improved Amputation-Free Survival in Infrageniculate Bypasses Performed by Prosthetic Grafts in Patients with Chronic Limb-Threatening Ischemia. Ann Vasc Surg. 2025. PMID: 40449885. doi:10.1016/j.avsg.2025.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。